$CNO
CNO Financial Group, Inc. Stock $cno

$cno Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000122460823000061 Filed on November 08, 2023

Income Statement

Concept	2023 Q4	2023 Q3
Revenue	$1.182B	$947.5M
YoY Change	21.38%	4.66%
Cost Of Revenue		$399.1M
YoY Change		-3.18%
Gross Profit		$548.4M
YoY Change		11.21%
Gross Profit Margin		57.88%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$1.045B	$703.1M
YoY Change	20.11%	-3.75%
Operating Profit		$129.8M
YoY Change		74.7%
Interest Expense	-$79.00M	$62.60M
YoY Change	65.27%	66.49%
% of Operating Profit		48.23%
Other Income/Expense, Net
YoY Change
Pretax Income	$46.10M	$215.6M
YoY Change	-16.79%	57.14%
Income Tax	$9.800M	$48.30M
% Of Pretax Income	21.26%	22.4%
Net Earnings	$36.30M	$167.3M
YoY Change	-16.36%	59.33%
Net Earnings / Revenue	3.07%	17.66%
Basic Earnings Per Share	$0.33	$1.48
Diluted Earnings Per Share	$0.32	$1.46
COMMON SHARES
Basic Shares Outstanding	112.2M shares	113.0M shares
Diluted Shares Outstanding		114.5M shares

Balance Sheet

Concept	2023 Q4	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents	$889.0M	$582.8M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment	$85.30M
YoY Change	83.05%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$26.14B	$24.70B
YoY Change	7.39%	2.33%
Other Assets	$936.2M	$1.040B
YoY Change	-19.67%	-11.9%
Total Long-Term Assets
YoY Change
TOTAL ASSETS
Total Short-Term Assets
Total Long-Term Assets
Total Assets	$35.10B	$33.51B
YoY Change	5.29%	1.42%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt	$4.151B	$4.148B
YoY Change	6.89%	6.53%
Other Long-Term Liabilities	$848.8M	$869.6M
YoY Change	22.32%	16.04%
Total Long-Term Liabilities	$4.999B	$5.018B
YoY Change	9.23%	8.07%
TOTAL LIABILITIES
Total Short-Term Liabilities
Total Long-Term Liabilities	$4.999B	$5.018B
Total Liabilities	$32.89B	$31.62B
YoY Change	2.97%	-0.38%
SHAREHOLDERS EQUITY
Retained Earnings	$1.900B	$1.880B
YoY Change	30.21%	31.32%
Common Stock	$1.893B	$1.966B
YoY Change	-6.99%	-3.21%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$2.216B	$1.890B
YoY Change
Total Liabilities & Shareholders Equity	$35.10B	$33.51B
YoY Change	5.29%	1.42%

Cashflow Statement

Concept	2023 Q4	2023 Q3
OPERATING ACTIVITIES
Net Income	$36.30M	$167.3M
YoY Change	-16.36%	59.33%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	$176.7M	$182.8M
YoY Change	9.82%	9.13%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$73.00M	-$393.4M
YoY Change	-134.21%	16.53%
Cash From Investing Activities	$73.00M	-$393.4M
YoY Change	-134.21%	16.53%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	56.50M	231.5M
YoY Change	-60.74%	122.17%
NET CHANGE
Cash From Operating Activities	176.7M	182.8M
Cash From Investing Activities	73.00M	-393.4M
Cash From Financing Activities	56.50M	231.5M
Net Change In Cash	306.2M	20.90M
YoY Change	235.01%	-131.71%
FREE CASH FLOW
Cash From Operating Activities	$176.7M	$182.8M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q3	cno	Available For Sale Fixed Maturities With Significant Unobservable Inputs Investment Grade Percent AvailableForSaleFixedMaturitiesWithSignificantUnobservableInputsInvestmentGradePercent	0.84
CY2023Q3	cno	Available For Sale Maturities With Significant Unobservable Inputs Corporate Securities Percent AvailableForSaleMaturitiesWithSignificantUnobservableInputsCorporateSecuritiesPercent	0.69
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	112163169	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	112163169	shares
	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	170000000.0	usd
	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	48700000	usd
	cno	Stock Based Compensation StockBasedCompensation	16300000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	1863400000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1768800000	usd
	us-gaap	Net Income Loss NetIncomeLoss	240200000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	600000	usd
	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	85100000	usd
	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	51000000.0	usd
	cno	Stock Based Compensation StockBasedCompensation	16600000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	1890100000	usd
	us-gaap	Proceeds From Insurance Premiums Collected ProceedsFromInsurancePremiumsCollected	1724900000	usd
	us-gaap	Proceeds From Interest And Dividends Received ProceedsFromInterestAndDividendsReceived	832200000	usd
	us-gaap	Proceeds From Fees Received ProceedsFromFeesReceived	110400000	usd
	cno	Insurance Policy Benefits InsurancePolicyBenefits	1243400000	usd
	us-gaap	Interest Paid Net InterestPaidNet	65800000	usd
	cno	Policy Acquisition Costs PolicyAcquisitionCosts	248500000	usd
	us-gaap	Payments For Other Operating Activities PaymentsForOtherOperatingActivities	754600000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	20700000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	334500000	usd
	cno	Sales Of Investments SalesOfInvestments	2764900000	usd
	cno	Maturities And Redemptions Of Investments MaturitiesAndRedemptionsOfInvestments	1265100000	usd
	cno	Purchases Of Investments PurchasesOfInvestments	5521100000	usd
	us-gaap	Proceeds From Payments For Trading Securities ProceedsFromPaymentsForTradingSecurities	-37400000	usd
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	39400000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1567900000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	11100000	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	95800000	usd
	us-gaap	Payments Of Dividends PaymentsOfDividends	51400000	usd
	cno	Proceeds From Financing Arrangements ProceedsFromFinancingArrangements	78200000	usd
	us-gaap	Proceeds From Annuities And Investment Certificates ProceedsFromAnnuitiesAndInvestmentCertificates	1537600000	usd
	us-gaap	Proceeds From Annuities And Investment Certificates ProceedsFromAnnuitiesAndInvestmentCertificates	2457800000	usd
	us-gaap	Repayments Of Annuities And Investment Certificates RepaymentsOfAnnuitiesAndInvestmentCertificates	1265800000	usd
	us-gaap	Repayments Of Annuities And Investment Certificates RepaymentsOfAnnuitiesAndInvestmentCertificates	1071000000	usd
	us-gaap	Proceeds From Federal Home Loan Bank Borrowings ProceedsFromFederalHomeLoanBankBorrowings	895500000	usd
	us-gaap	Proceeds From Federal Home Loan Bank Borrowings ProceedsFromFederalHomeLoanBankBorrowings	210000000.0	usd
	us-gaap	Repayments Of Federal Home Loan Bank Borrowings RepaymentsOfFederalHomeLoanBankBorrowings	445600000	usd
	us-gaap	Repayments Of Federal Home Loan Bank Borrowings RepaymentsOfFederalHomeLoanBankBorrowings	285900000	usd
	cno	Repayments Of Investment Borrowings Related To Variable Interest Entities RepaymentsOfInvestmentBorrowingsRelatedToVariableInterestEntities	186800000	usd
	cno	Repayments Of Investment Borrowings Related To Variable Interest Entities RepaymentsOfInvestmentBorrowingsRelatedToVariableInterestEntities	33400000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	477000000.0	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1055200000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-62100000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-178200000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	644900000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	731700000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	582800000	usd
CY2023Q3	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue	9723200000	usd
CY2023Q3	cno	Available For Sale Securities Debt Maturities Amortized Cost Excluding Structured Securities AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostExcludingStructuredSecurities	16448100000	usd
CY2023Q3	cno	Available For Sale Securities Debt Maturities Fair Value Excluding Structured Securities AvailableForSaleSecuritiesDebtMaturitiesFairValueExcludingStructuredSecurities	13506300000	usd
CY2023Q3	cno	Fixed Indexed Annuity Insurance Liabilities FixedIndexedAnnuityInsuranceLiabilities	9497900000	usd
CY2022Q4	cno	Fixed Indexed Annuity Insurance Liabilities FixedIndexedAnnuityInsuranceLiabilities	9153400000	usd
CY2023Q3	cno	Fixed Indexed Annuity Insurance Liabilities FixedIndexedAnnuityInsuranceLiabilities	9497900000	usd
CY2022Q4	cno	Fixed Indexed Annuity Insurance Liabilities FixedIndexedAnnuityInsuranceLiabilities	9153400000	usd
CY2021Q1	us-gaap	Value Of Business Acquired Voba ValueOfBusinessAcquiredVOBA	259600000	usd
CY2021Q1	us-gaap	Deferred Policy Acquisition Costs DeferredPolicyAcquisitionCosts	1485800000	usd
CY2021Q1	us-gaap	Reinsurance Recoverables Gross ReinsuranceRecoverablesGross	4728400000	usd
CY2021Q1	us-gaap	Market Risk Benefit Asset Amount MarketRiskBenefitAssetAmount	2500000	usd
CY2021Q1	cno	Deferred Income Tax Assets Net Including Netof Current Income Tax Payable DeferredIncomeTaxAssetsNetIncludingNetofCurrentIncomeTaxPayable	806400000	usd
CY2021Q1	us-gaap	Policyholder Funds PolicyholderFunds	12367700000	usd
CY2021Q1	us-gaap	Liability For Future Policy Benefits LiabilityForFuturePolicyBenefits	15704900000	usd
CY2021Q1	us-gaap	Market Risk Benefit Liability Amount MarketRiskBenefitLiabilityAmount	114800000	usd
CY2021Q1	us-gaap	Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense	91700000	usd
CY2023Q3	cno	Accumulated Other Comprehensive Income Loss Net Unrealized Appreciation On Investments Having No Allowance For Credit Losses AccumulatedOtherComprehensiveIncomeLossNetUnrealizedAppreciationOnInvestmentsHavingNoAllowanceForCreditLosses	-1506200000	usd
CY2022Q4	cno	Accumulated Other Comprehensive Income Loss Net Unrealized Appreciation On Investments Having No Allowance For Credit Losses AccumulatedOtherComprehensiveIncomeLossNetUnrealizedAppreciationOnInvestmentsHavingNoAllowanceForCreditLosses	-1247000000	usd
CY2023Q3	cno	Accumulated Other Comprehensive Income Loss Net Unrealized Appreciation On Investments With Allowance For Credit Losses AccumulatedOtherComprehensiveIncomeLossNetUnrealizedAppreciationOnInvestmentsWithAllowanceForCreditLosses	-2038500000	usd
CY2022Q4	cno	Accumulated Other Comprehensive Income Loss Net Unrealized Appreciation On Investments With Allowance For Credit Losses AccumulatedOtherComprehensiveIncomeLossNetUnrealizedAppreciationOnInvestmentsWithAllowanceForCreditLosses	-1780700000	usd
CY2023Q3	cno	Accumulated Other Comprehensive Income Loss Changes In Discount Rate For Liability For Future Policy Benefit AccumulatedOtherComprehensiveIncomeLossChangesInDiscountRateForLiabilityForFuturePolicyBenefit	1021600000	usd
CY2022Q4	cno	Accumulated Other Comprehensive Income Loss Changes In Discount Rate For Liability For Future Policy Benefit AccumulatedOtherComprehensiveIncomeLossChangesInDiscountRateForLiabilityForFuturePolicyBenefit	500700000	usd
CY2023Q3	cno	Accumulated Other Comprehensive Income Loss Changed In Instrument Specific Credit Risk For Market Risk Benefits AccumulatedOtherComprehensiveIncomeLossChangedInInstrumentSpecificCreditRiskForMarketRiskBenefits	7800000	usd
CY2022Q4	cno	Accumulated Other Comprehensive Income Loss Changed In Instrument Specific Credit Risk For Market Risk Benefits AccumulatedOtherComprehensiveIncomeLossChangedInInstrumentSpecificCreditRiskForMarketRiskBenefits	12200000	usd
CY2023Q3	cno	Accumulated Other Comprehensive Income Loss Deferred Income Tax Liabilities AccumulatedOtherComprehensiveIncomeLossDeferredIncomeTaxLiabilities	558600000	usd
CY2022Q4	cno	Accumulated Other Comprehensive Income Loss Deferred Income Tax Liabilities AccumulatedOtherComprehensiveIncomeLossDeferredIncomeTaxLiabilities	557500000	usd
CY2023Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1956700000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1957300000	usd
CY2023Q3	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	171900000	usd
CY2023Q3	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	161900000	usd
CY2023Q3	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	2217500000	usd
CY2023Q3	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	2069500000	usd
CY2023Q3	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost	1729000000	usd
CY2023Q3	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue	1551700000	usd
CY2023Q3	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost	12329700000	usd
CY2023Q3	us-gaap	Available For Sale Securities Debt Maturities Without Single Maturity Date Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost	7451400000	usd
CY2023Q3	us-gaap	Available For Sale Securities Debt Maturities Without Single Maturity Date Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue	6798900000	usd
CY2023Q3	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss	23899500000	usd
CY2023Q3	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	20305200000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	112000000.0	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	110800000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	1913700000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	1790200000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost	2098900000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue	1910400000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost	12629400000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue	10523200000	usd
CY2022Q4	cno	Available For Sale Securities Debt Maturities Amortized Cost Excluding Structured Securities AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostExcludingStructuredSecurities	16754000000	usd
CY2022Q4	cno	Available For Sale Securities Debt Maturities Fair Value Excluding Structured Securities AvailableForSaleSecuritiesDebtMaturitiesFairValueExcludingStructuredSecurities	14334600000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Without Single Maturity Date Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost	6630200000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Without Single Maturity Date Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue	6018800000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss	23384200000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	20353400000	usd
CY2023Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	2212800000	usd
CY2023Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	108100000	usd
CY2023Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	8074100000	usd
CY2023Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	1442700000	usd
CY2023Q3	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	10286900000	usd
CY2023Q3	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	1550800000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	7636900000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	835200000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	1897500000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	471600000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	9534400000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	1306800000	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest	66100000	usd
CY2023Q3	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded	1300000	usd
CY2023Q3	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Purchased With Credit Deterioration Increase DebtSecuritiesAvailableForSaleAllowanceForCreditLossPurchasedWithCreditDeteriorationIncrease	0	usd
CY2023Q3	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Not To Sell Before Recovery Credit Loss Previously Recorded Expense Reversal DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotToSellBeforeRecoveryCreditLossPreviouslyRecordedExpenseReversal	2300000	usd
CY2023Q3	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Securities Sold DebtSecuritiesAvailableForSaleAllowanceForCreditLossSecuritiesSold	300000	usd
CY2023Q3	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Sell Before Recovery DebtSecuritiesAvailableForSaleAllowanceForCreditLossSellBeforeRecovery	0	usd
CY2023Q3	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Writeoff DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff	0	usd
CY2023Q3	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Recovery DebtSecuritiesAvailableForSaleAllowanceForCreditLossRecovery	0	usd
CY2023Q3	us-gaap	Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest	69400000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest	56000000.0	usd
	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded	6200000	usd
	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Purchased With Credit Deterioration Increase DebtSecuritiesAvailableForSaleAllowanceForCreditLossPurchasedWithCreditDeteriorationIncrease	0	usd
	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Not To Sell Before Recovery Credit Loss Previously Recorded Expense Reversal DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotToSellBeforeRecoveryCreditLossPreviouslyRecordedExpenseReversal	9900000	usd
	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Securities Sold DebtSecuritiesAvailableForSaleAllowanceForCreditLossSecuritiesSold	2700000	usd
	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Sell Before Recovery DebtSecuritiesAvailableForSaleAllowanceForCreditLossSellBeforeRecovery	0	usd
	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Writeoff DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff	0	usd
	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Recovery DebtSecuritiesAvailableForSaleAllowanceForCreditLossRecovery	0	usd
CY2023Q3	us-gaap	Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest	69400000	usd
CY2022Q2	us-gaap	Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest	54200000	usd
CY2022Q3	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded	7600000	usd
CY2022Q3	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Purchased With Credit Deterioration Increase DebtSecuritiesAvailableForSaleAllowanceForCreditLossPurchasedWithCreditDeteriorationIncrease	0	usd
CY2022Q3	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Not To Sell Before Recovery Credit Loss Previously Recorded Expense Reversal DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotToSellBeforeRecoveryCreditLossPreviouslyRecordedExpenseReversal	-6400000	usd
CY2022Q3	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Securities Sold DebtSecuritiesAvailableForSaleAllowanceForCreditLossSecuritiesSold	3400000	usd
CY2022Q3	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Sell Before Recovery DebtSecuritiesAvailableForSaleAllowanceForCreditLossSellBeforeRecovery	0	usd
CY2022Q3	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Writeoff DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff	0	usd
CY2022Q3	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Recovery DebtSecuritiesAvailableForSaleAllowanceForCreditLossRecovery	0	usd
CY2022Q3	us-gaap	Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest	52000000.0	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest	7600000	usd
	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded	41200000	usd
	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Purchased With Credit Deterioration Increase DebtSecuritiesAvailableForSaleAllowanceForCreditLossPurchasedWithCreditDeteriorationIncrease	0	usd
	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Not To Sell Before Recovery Credit Loss Previously Recorded Expense Reversal DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotToSellBeforeRecoveryCreditLossPreviouslyRecordedExpenseReversal	13100000	usd
	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Securities Sold DebtSecuritiesAvailableForSaleAllowanceForCreditLossSecuritiesSold	9900000	usd
	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Sell Before Recovery DebtSecuritiesAvailableForSaleAllowanceForCreditLossSellBeforeRecovery	0	usd
	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Writeoff DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff	0	usd
	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Recovery DebtSecuritiesAvailableForSaleAllowanceForCreditLossRecovery	0	usd
CY2022Q3	us-gaap	Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest	52000000.0	usd
CY2023Q2	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	10300000	usd
CY2022Q2	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	4900000	usd
CY2023Q3	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	-600000	usd
CY2022Q3	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	-400000	usd
CY2023Q3	us-gaap	Financing Receivable Allowance For Credit Loss Purchased With Credit Deterioration Increase FinancingReceivableAllowanceForCreditLossPurchasedWithCreditDeteriorationIncrease	0	usd
CY2022Q3	us-gaap	Financing Receivable Allowance For Credit Loss Purchased With Credit Deterioration Increase FinancingReceivableAllowanceForCreditLossPurchasedWithCreditDeteriorationIncrease	0	usd
CY2023Q3	us-gaap	Financing Receivable Allowance For Credit Losses Write Offs FinancingReceivableAllowanceForCreditLossesWriteOffs	0	usd
CY2022Q3	us-gaap	Financing Receivable Allowance For Credit Losses Write Offs FinancingReceivableAllowanceForCreditLossesWriteOffs	0	usd
CY2023Q3	us-gaap	Financing Receivable Allowance For Credit Losses Recovery FinancingReceivableAllowanceForCreditLossesRecovery	0	usd
CY2022Q3	us-gaap	Financing Receivable Allowance For Credit Losses Recovery FinancingReceivableAllowanceForCreditLossesRecovery	0	usd
CY2023Q3	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	10900000	usd
CY2022Q3	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	5300000	usd
CY2022Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	8000000.0	usd
CY2021Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	5600000	usd
	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	-2900000	usd
	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	300000	usd
	us-gaap	Financing Receivable Allowance For Credit Loss Purchased With Credit Deterioration Increase FinancingReceivableAllowanceForCreditLossPurchasedWithCreditDeteriorationIncrease	0	usd
	us-gaap	Financing Receivable Allowance For Credit Loss Purchased With Credit Deterioration Increase FinancingReceivableAllowanceForCreditLossPurchasedWithCreditDeteriorationIncrease	0	usd
	us-gaap	Financing Receivable Allowance For Credit Losses Write Offs FinancingReceivableAllowanceForCreditLossesWriteOffs	0	usd
	us-gaap	Financing Receivable Allowance For Credit Losses Write Offs FinancingReceivableAllowanceForCreditLossesWriteOffs	0	usd
	us-gaap	Financing Receivable Allowance For Credit Losses Recovery FinancingReceivableAllowanceForCreditLossesRecovery	0	usd
	us-gaap	Financing Receivable Allowance For Credit Losses Recovery FinancingReceivableAllowanceForCreditLossesRecovery	0	usd
CY2023Q3	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	10900000	usd
CY2022Q3	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	5300000	usd
CY2023Q3	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-21600000	usd
CY2022Q3	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-8200000	usd
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-58000000.0	usd
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	3600000	usd
CY2023Q3	cno	Debt Securities Available For Sale And Other Investments Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAndOtherInvestmentsAllowanceForCreditLossPeriodIncreaseDecrease	2300000	usd
CY2022Q3	cno	Debt Securities Available For Sale And Other Investments Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAndOtherInvestmentsAllowanceForCreditLossPeriodIncreaseDecrease	-7500000	usd
	cno	Debt Securities Available For Sale And Other Investments Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAndOtherInvestmentsAllowanceForCreditLossPeriodIncreaseDecrease	13700000	usd
	cno	Debt Securities Available For Sale And Other Investments Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAndOtherInvestmentsAllowanceForCreditLossPeriodIncreaseDecrease	46900000	usd
CY2023Q3	us-gaap	Increase Decrease In Equity Securities Fv Ni IncreaseDecreaseInEquitySecuritiesFvNi	-900000	usd
CY2022Q3	us-gaap	Increase Decrease In Equity Securities Fv Ni IncreaseDecreaseInEquitySecuritiesFvNi	-700000	usd
	us-gaap	Increase Decrease In Equity Securities Fv Ni IncreaseDecreaseInEquitySecuritiesFvNi	-500000	usd
	us-gaap	Increase Decrease In Equity Securities Fv Ni IncreaseDecreaseInEquitySecuritiesFvNi	-2400000	usd
CY2023Q3	cno	Increase Decrease In Fair Value Of Other Securities IncreaseDecreaseInFairValueOfOtherSecurities	-4500000	usd
CY2022Q3	cno	Increase Decrease In Fair Value Of Other Securities IncreaseDecreaseInFairValueOfOtherSecurities	-16300000	usd
	cno	Increase Decrease In Fair Value Of Other Securities IncreaseDecreaseInFairValueOfOtherSecurities	-7000000.0	usd
	cno	Increase Decrease In Fair Value Of Other Securities IncreaseDecreaseInFairValueOfOtherSecurities	-53500000	usd
CY2023Q3	cno	Other Investments Gain Loss OtherInvestmentsGainLoss	-7700000	usd
CY2022Q3	cno	Other Investments Gain Loss OtherInvestmentsGainLoss	-9500000	usd
	cno	Other Investments Gain Loss OtherInvestmentsGainLoss	-21200000	usd
	cno	Other Investments Gain Loss OtherInvestmentsGainLoss	-102800000	usd
CY2023Q3	us-gaap	Gain Loss On Investments GainLossOnInvestments	-29300000	usd
CY2022Q3	us-gaap	Gain Loss On Investments GainLossOnInvestments	-17700000	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	-79200000	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	-99200000	usd
CY2023Q3	cno	Variable Interest Entities Change In Allowance For Current Expected Credit Losses VariableInterestEntitiesChangeInAllowanceForCurrentExpectedCreditLosses	-1600000	usd
CY2022Q3	cno	Variable Interest Entities Change In Allowance For Current Expected Credit Losses VariableInterestEntitiesChangeInAllowanceForCurrentExpectedCreditLosses	-5700000	usd
	cno	Variable Interest Entities Change In Allowance For Current Expected Credit Losses VariableInterestEntitiesChangeInAllowanceForCurrentExpectedCreditLosses	-2600000	usd
	cno	Variable Interest Entities Change In Allowance For Current Expected Credit Losses VariableInterestEntitiesChangeInAllowanceForCurrentExpectedCreditLosses	2800000	usd
	cno	Increase Decrease In Equity Securities Fvni Held At End Of Period IncreaseDecreaseInEquitySecuritiesFVNIHeldAtEndOfPeriod	-700000	usd
	cno	Increase Decrease In Equity Securities Fvni Held At End Of Period IncreaseDecreaseInEquitySecuritiesFVNIHeldAtEndOfPeriod	-6900000	usd
	us-gaap	Increase Decrease In Debt Securities Trading IncreaseDecreaseInDebtSecuritiesTrading	-8000000.0	usd
	us-gaap	Increase Decrease In Debt Securities Trading IncreaseDecreaseInDebtSecuritiesTrading	-36600000	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	-79200000	usd
	cno	Debt Securities Available For Sale And Other Investments Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAndOtherInvestmentsAllowanceForCreditLossPeriodIncreaseDecrease	13700000	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	-99200000	usd
	cno	Debt Securities Available For Sale And Other Investments Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAndOtherInvestmentsAllowanceForCreditLossPeriodIncreaseDecrease	46900000	usd
CY2023Q3	cno	Numberof Investmentsin Defaultor Considered Nonperforming NumberofInvestmentsinDefaultorConsideredNonperforming	0	investment
	cno	Available For Sale Securities Value Of Securities Sold AvailableForSaleSecuritiesValueOfSecuritiesSold	527000000	usd
	cno	Available For Sale Securities Value Of Securities Sold AvailableForSaleSecuritiesValueOfSecuritiesSold	1321700000	usd
CY2023Q3	cno	Liability For Future Policy Benefit Before Reinsurance Reserve LiabilityForFuturePolicyBenefitBeforeReinsuranceReserve	2574000000	usd
CY2022Q3	cno	Liability For Future Policy Benefit Before Reinsurance Reserve LiabilityForFuturePolicyBenefitBeforeReinsuranceReserve	2616100000	usd
CY2023Q3	cno	Liability For Future Policy Benefit Deferred Profit Liability LiabilityForFuturePolicyBenefitDeferredProfitLiability	60800000	usd
CY2022Q3	cno	Liability For Future Policy Benefit Deferred Profit Liability LiabilityForFuturePolicyBenefitDeferredProfitLiability	50400000	usd
CY2023Q3	cno	Liability For Future Policy Benefit Fas Reserves Excluding Policyholder LiabilityForFuturePolicyBenefitFASReservesExcludingPolicyholder	454700000	usd
CY2022Q3	cno	Liability For Future Policy Benefit Fas Reserves Excluding Policyholder LiabilityForFuturePolicyBenefitFASReservesExcludingPolicyholder	569800000	usd
CY2023Q3	cno	Liability For Future Policy Benefits Payment For Benefits Reserve LiabilityForFuturePolicyBenefitsPaymentForBenefitsReserve	34600000	usd
CY2022Q3	cno	Liability For Future Policy Benefits Payment For Benefits Reserve LiabilityForFuturePolicyBenefitsPaymentForBenefitsReserve	34100000	usd
CY2023Q3	cno	Policyholder Account Balance Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense PolicyholderAccountBalanceLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense	10829900000	usd
CY2022Q3	cno	Policyholder Account Balance Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense PolicyholderAccountBalanceLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense	10815500000	usd
CY2022Q4	us-gaap	Market Risk Benefit After Increase Decrease From Instrument Specific Credit Risk MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk	-54000000.0	usd
CY2021Q4	us-gaap	Market Risk Benefit After Increase Decrease From Instrument Specific Credit Risk MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk	86200000	usd
CY2022Q4	cno	Market Risk Benefit Effect Of Changes In Instrument Specific Credit Risk MarketRiskBenefitEffectOfChangesInInstrumentSpecificCreditRisk	12200000	usd
CY2021Q4	cno	Market Risk Benefit Effect Of Changes In Instrument Specific Credit Risk MarketRiskBenefitEffectOfChangesInInstrumentSpecificCreditRisk	12100000	usd
CY2022Q4	us-gaap	Market Risk Benefit Before Reinsurance And Cumulative Increase Decrease From Instrument Specific Credit Risk Change MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange	-41800000	usd
CY2021Q4	us-gaap	Market Risk Benefit Before Reinsurance And Cumulative Increase Decrease From Instrument Specific Credit Risk Change MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange	98300000	usd
	cno	Market Risk Benefit Issuance Net MarketRiskBenefitIssuanceNet	-400000	usd
	cno	Market Risk Benefit Issuance Net MarketRiskBenefitIssuanceNet	-1500000	usd
	us-gaap	Market Risk Benefit Interest Expense MarketRiskBenefitInterestExpense	15800000	usd
	us-gaap	Market Risk Benefit Interest Expense MarketRiskBenefitInterestExpense	11600000	usd
	us-gaap	Market Risk Benefit Attributed Fee Collected MarketRiskBenefitAttributedFeeCollected	0	usd
	us-gaap	Market Risk Benefit Attributed Fee Collected MarketRiskBenefitAttributedFeeCollected	0	usd
	us-gaap	Market Risk Benefit Benefit Payment MarketRiskBenefitBenefitPayment	0	usd
	us-gaap	Market Risk Benefit Benefit Payment MarketRiskBenefitBenefitPayment	0	usd
	us-gaap	Market Risk Benefit Increase Decrease From Interest Rate Change MarketRiskBenefitIncreaseDecreaseFromInterestRateChange	-36200000	usd
	us-gaap	Market Risk Benefit Increase Decrease From Interest Rate Change MarketRiskBenefitIncreaseDecreaseFromInterestRateChange	-140300000	usd
	us-gaap	Market Risk Benefit Increase Decrease From Equity Market Change MarketRiskBenefitIncreaseDecreaseFromEquityMarketChange	4100000	usd
	us-gaap	Market Risk Benefit Increase Decrease From Equity Market Change MarketRiskBenefitIncreaseDecreaseFromEquityMarketChange	-7900000	usd
	us-gaap	Market Risk Benefit Increase Decrease From Volatility MarketRiskBenefitIncreaseDecreaseFromVolatility	-17500000	usd
	us-gaap	Market Risk Benefit Increase Decrease From Volatility MarketRiskBenefitIncreaseDecreaseFromVolatility	20600000	usd
	us-gaap	Market Risk Benefit Increase Decrease From Actual Policyholder Behavior Different From Expected MarketRiskBenefitIncreaseDecreaseFromActualPolicyholderBehaviorDifferentFromExpected	2500000	usd
	us-gaap	Market Risk Benefit Increase Decrease From Actual Policyholder Behavior Different From Expected MarketRiskBenefitIncreaseDecreaseFromActualPolicyholderBehaviorDifferentFromExpected	100000	usd
	cno	Market Risk Benefit Increase Decrease From Future Expected Policyholder Behavior Assumption Other MarketRiskBenefitIncreaseDecreaseFromFutureExpectedPolicyholderBehaviorAssumptionOther	0	usd
	cno	Market Risk Benefit Increase Decrease From Future Expected Policyholder Behavior Assumption Other MarketRiskBenefitIncreaseDecreaseFromFutureExpectedPolicyholderBehaviorAssumptionOther	0	usd
	cno	Market Risk Benefit Increase Decrease From Future Expected Policyholder Behavior Assumption Risk Margin MarketRiskBenefitIncreaseDecreaseFromFutureExpectedPolicyholderBehaviorAssumptionRiskMargin	0	usd
	cno	Market Risk Benefit Increase Decrease From Future Expected Policyholder Behavior Assumption Risk Margin MarketRiskBenefitIncreaseDecreaseFromFutureExpectedPolicyholderBehaviorAssumptionRiskMargin	0	usd
	us-gaap	Market Risk Benefit Increase Decrease From Other Assumption MarketRiskBenefitIncreaseDecreaseFromOtherAssumption	-4900000	usd
	us-gaap	Market Risk Benefit Increase Decrease From Other Assumption MarketRiskBenefitIncreaseDecreaseFromOtherAssumption	-400000	usd
CY2023Q3	us-gaap	Market Risk Benefit Before Reinsurance And Cumulative Increase Decrease From Instrument Specific Credit Risk Change MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange	-78400000	usd
CY2022Q3	us-gaap	Market Risk Benefit Before Reinsurance And Cumulative Increase Decrease From Instrument Specific Credit Risk Change MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange	-19500000	usd
CY2023Q3	cno	Market Risk Benefit Effect Of Changes In Instrument Specific Credit Risk MarketRiskBenefitEffectOfChangesInInstrumentSpecificCreditRisk	7800000	usd
CY2022Q3	cno	Market Risk Benefit Effect Of Changes In Instrument Specific Credit Risk MarketRiskBenefitEffectOfChangesInInstrumentSpecificCreditRisk	23100000	usd
CY2023Q3	us-gaap	Market Risk Benefit After Increase Decrease From Instrument Specific Credit Risk MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk	-86200000	usd
CY2022Q3	us-gaap	Market Risk Benefit After Increase Decrease From Instrument Specific Credit Risk MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk	-42600000	usd
CY2023Q3	us-gaap	Market Risk Benefit Reinsurance Recoverable After Allowance MarketRiskBenefitReinsuranceRecoverableAfterAllowance	0	usd
CY2022Q3	us-gaap	Market Risk Benefit Reinsurance Recoverable After Allowance MarketRiskBenefitReinsuranceRecoverableAfterAllowance	0	usd
CY2023Q3	us-gaap	Market Risk Benefit After Reinsurance And Cumulative Increase Decrease From Instrument Specific Credit Risk Change MarketRiskBenefitAfterReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange	-86200000	usd
CY2022Q3	us-gaap	Market Risk Benefit After Reinsurance And Cumulative Increase Decrease From Instrument Specific Credit Risk Change MarketRiskBenefitAfterReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange	-42600000	usd
CY2023Q3	us-gaap	Market Risk Benefit Asset Amount MarketRiskBenefitAssetAmount	89300000	usd
CY2022Q3	us-gaap	Market Risk Benefit Asset Amount MarketRiskBenefitAssetAmount	56300000	usd
CY2023Q3	us-gaap	Market Risk Benefit Liability Amount MarketRiskBenefitLiabilityAmount	3100000	usd
CY2022Q3	us-gaap	Market Risk Benefit Liability Amount MarketRiskBenefitLiabilityAmount	13700000	usd
CY2023Q3	us-gaap	Market Risk Benefit After Increase Decrease From Instrument Specific Credit Risk MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk	-86200000	usd
CY2022Q3	us-gaap	Market Risk Benefit After Increase Decrease From Instrument Specific Credit Risk MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk	-42600000	usd
CY2023Q3	us-gaap	Market Risk Benefit Net Amount At Risk MarketRiskBenefitNetAmountAtRisk	51000000.0	usd
CY2022Q3	us-gaap	Market Risk Benefit Net Amount At Risk MarketRiskBenefitNetAmountAtRisk	51700000	usd
	us-gaap	Net Amount At Risk By Product And Guarantee Weighted Average Attained Age1 NetAmountAtRiskByProductAndGuaranteeWeightedAverageAttainedAge1	P69Y
	us-gaap	Net Amount At Risk By Product And Guarantee Weighted Average Attained Age1 NetAmountAtRiskByProductAndGuaranteeWeightedAverageAttainedAge1	P68Y
	us-gaap	Liability For Future Policy Benefit Gross Premium Income LiabilityForFuturePolicyBenefitGrossPremiumIncome	1767100000	usd
	us-gaap	Liability For Future Policy Benefit Gross Premium Income LiabilityForFuturePolicyBenefitGrossPremiumIncome	1778800000	usd
	us-gaap	Liability For Future Policy Benefit Interest Expense LiabilityForFuturePolicyBenefitInterestExpense	359500000	usd
	us-gaap	Liability For Future Policy Benefit Interest Expense LiabilityForFuturePolicyBenefitInterestExpense	355700000	usd
CY2023Q3	us-gaap	Policyholder Funds PolicyholderFunds	15481800000	usd
CY2022Q3	us-gaap	Policyholder Funds PolicyholderFunds	15079700000	usd
CY2023Q3	us-gaap	Policyholder Funds PolicyholderFunds	15481800000	usd
CY2022Q3	us-gaap	Policyholder Funds PolicyholderFunds	15079700000	usd
CY2022Q4	cno	Deferred Policy Acquisition Cost Net Of Sales Inducements DeferredPolicyAcquisitionCostNetOfSalesInducements	1690400000	usd
	us-gaap	Deferred Policy Acquisition Costs Additions DeferredPolicyAcquisitionCostsAdditions	260700000	usd
	us-gaap	Deferred Policy Acquisition Cost Amortization Expense DeferredPolicyAcquisitionCostAmortizationExpense	142400000	usd
CY2023Q3	cno	Deferred Policy Acquisition Cost Net Of Sales Inducements DeferredPolicyAcquisitionCostNetOfSalesInducements	1808700000	usd
CY2021Q4	cno	Deferred Policy Acquisition Cost Net Of Sales Inducements DeferredPolicyAcquisitionCostNetOfSalesInducements	1553300000	usd
	us-gaap	Deferred Policy Acquisition Costs Additions DeferredPolicyAcquisitionCostsAdditions	232700000	usd
	us-gaap	Deferred Policy Acquisition Cost Amortization Expense DeferredPolicyAcquisitionCostAmortizationExpense	131000000.0	usd
CY2022Q3	cno	Deferred Policy Acquisition Cost Net Of Sales Inducements DeferredPolicyAcquisitionCostNetOfSalesInducements	1655000000	usd
CY2022Q4	us-gaap	Value Of Business Acquired Voba ValueOfBusinessAcquiredVOBA	203700000	usd
	us-gaap	Present Value Of Future Insurance Profits Amortization Expense1 PresentValueOfFutureInsuranceProfitsAmortizationExpense1	17500000	usd
CY2023Q3	us-gaap	Value Of Business Acquired Voba ValueOfBusinessAcquiredVOBA	186200000	usd
CY2021Q4	us-gaap	Value Of Business Acquired Voba ValueOfBusinessAcquiredVOBA	230100000	usd
	us-gaap	Present Value Of Future Insurance Profits Amortization Expense1 PresentValueOfFutureInsuranceProfitsAmortizationExpense1	20100000	usd
CY2022Q3	us-gaap	Value Of Business Acquired Voba ValueOfBusinessAcquiredVOBA	210000000.0	usd
CY2023Q3	cno	Segment Revenues SegmentRevenues	959100000	usd
CY2022Q3	cno	Segment Revenues SegmentRevenues	910100000	usd
	cno	Segment Revenues SegmentRevenues	2999500000	usd
	cno	Segment Revenues SegmentRevenues	2675000000	usd
CY2023Q3	cno	Segment Expenses SegmentExpenses	829300000	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	167300000	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	167300000	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	175900000	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	175900000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	240200000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	240200000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	592600000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	592600000	usd
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	112689000	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	114354000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	113836000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	116170000	shares
CY2023Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1773000	shares
CY2022Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1574000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1777000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1902000	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	114462000	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	115928000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	115613000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	118072000	shares
	cno	Numberof Product Lines NumberofProductLines	3	product_line
	cno	Numberof Product Lines NumberofProductLines	3	product_line
CY2022Q3	cno	Segment Expenses SegmentExpenses	809100000	usd
	cno	Segment Expenses SegmentExpenses	2712100000	usd
	cno	Segment Expenses SegmentExpenses	2315300000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	129800000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	101000000.0	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	287400000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	359700000	usd
CY2023Q3	cno	Income Tax Benefit On Operating Income Loss IncomeTaxBenefitOnOperatingIncomeLoss	28500000	usd
CY2022Q3	cno	Income Tax Benefit On Operating Income Loss IncomeTaxBenefitOnOperatingIncomeLoss	23100000	usd
	cno	Income Tax Benefit On Operating Income Loss IncomeTaxBenefitOnOperatingIncomeLoss	65200000	usd
	cno	Income Tax Benefit On Operating Income Loss IncomeTaxBenefitOnOperatingIncomeLoss	82200000	usd
CY2023Q3	cno	Operating Income Loss Net Of Tax OperatingIncomeLossNetOfTax	101300000	usd
CY2022Q3	cno	Operating Income Loss Net Of Tax OperatingIncomeLossNetOfTax	77900000	usd
	cno	Operating Income Loss Net Of Tax OperatingIncomeLossNetOfTax	222200000	usd
	cno	Operating Income Loss Net Of Tax OperatingIncomeLossNetOfTax	277500000	usd
CY2023Q3	us-gaap	Revenues Revenues	947500000	usd
CY2022Q3	us-gaap	Revenues Revenues	905300000	usd
	us-gaap	Revenues Revenues	2976300000	usd
	us-gaap	Revenues Revenues	2603200000	usd
CY2023Q3	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	731900000	usd
CY2022Q3	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	677400000	usd
	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	2665600000	usd
	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	1835200000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	215600000	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	227900000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	310700000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	768000000.0	usd
CY2023Q3	cno	Income Tax Expense Benefit Before Valuation Allowance Adjustment IncomeTaxExpenseBenefitBeforeValuationAllowanceAdjustment	48300000	usd
CY2022Q3	cno	Income Tax Expense Benefit Before Valuation Allowance Adjustment IncomeTaxExpenseBenefitBeforeValuationAllowanceAdjustment	52000000.0	usd
	cno	Income Tax Expense Benefit Before Valuation Allowance Adjustment IncomeTaxExpenseBenefitBeforeValuationAllowanceAdjustment	70500000	usd
	cno	Income Tax Expense Benefit Before Valuation Allowance Adjustment IncomeTaxExpenseBenefitBeforeValuationAllowanceAdjustment	175400000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	167300000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	175900000	usd
	us-gaap	Net Income Loss NetIncomeLoss	240200000	usd
	us-gaap	Net Income Loss NetIncomeLoss	592600000	usd
CY2023Q3	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Net EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet	85000000	usd
CY2022Q3	us-gaap	Reinsurance Effect On Claims And Benefits Incurred Amount Assumed ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed	7200000	usd
CY2023Q3	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	-57200000	usd
CY2022Q3	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	-39100000	usd
	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	22400000	usd
	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	-216500000	usd
CY2023Q3	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	68600000	usd
CY2022Q3	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	90000000.0	usd
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	60100000	usd
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	309000000.0	usd
CY2023Q3	us-gaap	Ceded Premiums Written CededPremiumsWritten	46700000	usd
CY2022Q3	us-gaap	Ceded Premiums Written CededPremiumsWritten	51200000	usd
	us-gaap	Ceded Premiums Written CededPremiumsWritten	144700000	usd
	us-gaap	Ceded Premiums Written CededPremiumsWritten	152300000	usd
CY2023Q3	us-gaap	Reinsurance Effect On Claims And Benefits Incurred Amount Ceded ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded	98300000	usd
CY2022Q3	us-gaap	Reinsurance Effect On Claims And Benefits Incurred Amount Ceded ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded	95100000	usd
	us-gaap	Reinsurance Effect On Claims And Benefits Incurred Amount Ceded ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded	320100000	usd
	us-gaap	Reinsurance Effect On Claims And Benefits Incurred Amount Ceded ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded	296000000	usd
CY2023Q3	us-gaap	Assumed Premiums Written AssumedPremiumsWritten	4200000	usd
CY2022Q3	us-gaap	Assumed Premiums Written AssumedPremiumsWritten	4700000	usd
	us-gaap	Assumed Premiums Written AssumedPremiumsWritten	12600000	usd
	us-gaap	Assumed Premiums Written AssumedPremiumsWritten	14200000	usd
CY2023Q3	us-gaap	Reinsurance Effect On Claims And Benefits Incurred Amount Assumed ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed	5800000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Policyholder Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilities	312800000	usd
	us-gaap	Reinsurance Effect On Claims And Benefits Incurred Amount Assumed ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed	16300000	usd
	us-gaap	Reinsurance Effect On Claims And Benefits Incurred Amount Assumed ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed	19700000	usd
CY2023Q3	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	6300000	usd
CY2022Q3	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	14900000	usd
	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	40000000.0	usd
	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	19900000	usd
CY2023Q3	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	42000000.0	usd
CY2022Q3	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	37100000	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	30500000	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	155500000	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	48300000	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	52000000.0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	70500000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	175400000	usd
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.004
	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.001
	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.021
	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.019
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.227
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.228
CY2023Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	100100000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	166000000.0	usd
CY2023Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	2500000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	2500000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Policyholder Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilities	298500000	usd
CY2023Q3	cno	Deferred Tax Assets Indirect Costs Allocableto Self Constructed Real Estate Assets DeferredTaxAssetsIndirectCostsAllocabletoSelfConstructedRealEstateAssets	244500000	usd
CY2022Q4	cno	Deferred Tax Assets Indirect Costs Allocableto Self Constructed Real Estate Assets DeferredTaxAssetsIndirectCostsAllocabletoSelfConstructedRealEstateAssets	214800000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Other Comprehensive Loss DeferredTaxAssetsOtherComprehensiveLoss	552600000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other Comprehensive Loss DeferredTaxAssetsOtherComprehensiveLoss	552400000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2900000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	7300000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1215400000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1241500000	usd
CY2023Q3	us-gaap	Deferred Tax Liabilities Investments DeferredTaxLiabilitiesInvestments	30800000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Investments DeferredTaxLiabilitiesInvestments	37200000	usd
CY2023Q3	us-gaap	Deferred Tax Liabilities Deferred Expense Deferred Policy Acquisition Cost DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCost	158600000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Deferred Policy Acquisition Cost DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCost	148900000	usd
CY2023Q3	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	189400000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	186100000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	1026000000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	1055400000	usd
CY2023Q3	cno	Prepaid Accrued Income Taxes Current PrepaidAccruedIncomeTaxesCurrent	13800000	usd
CY2022Q4	cno	Prepaid Accrued Income Taxes Current PrepaidAccruedIncomeTaxesCurrent	8000000.0	usd
CY2023Q3	cno	Deferred Income Tax Assets Net Including Netof Current Income Tax Payable DeferredIncomeTaxAssetsNetIncludingNetofCurrentIncomeTaxPayable	1039800000	usd
CY2022Q4	cno	Deferred Income Tax Assets Net Including Netof Current Income Tax Payable DeferredIncomeTaxAssetsNetIncludingNetofCurrentIncomeTaxPayable	1063400000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	1026000000	usd
CY2023Q3	cno	Loss Limitation Based On Income Of Life Insurance Company LossLimitationBasedOnIncomeOfLifeInsuranceCompany	0.35
CY2023Q3	cno	Loss Limitation Based On Loss Of Non Life Entities LossLimitationBasedOnLossOfNonLifeEntities	0.35
CY2023Q3	cno	Federal Long Term Tax Exempt Rate FederalLongTermTaxExemptRate	0.0317
CY2023Q3	cno	Ownership Change Threshold Restricting Net Operating Loss Usage OwnershipChangeThresholdRestrictingNetOperatingLossUsage	0.50
CY2023Q3	cno	Nonoperating Loss Carryforwards NonoperatingLossCarryforwards	476600000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	2500000	usd
CY2023Q3	us-gaap	Deferred Finance Costs Noncurrent Gross DeferredFinanceCostsNoncurrentGross	9900000	usd
CY2022Q4	us-gaap	Deferred Finance Costs Noncurrent Gross DeferredFinanceCostsNoncurrentGross	11200000	usd
CY2023Q3	us-gaap	Notes Payable NotesPayable	1140100000	usd
CY2022Q4	us-gaap	Notes Payable NotesPayable	1138800000	usd
	cno	Number Of Insurance Subsidiaries That Are Members Of The Federal Home Loan Bank NumberOfInsuranceSubsidiariesThatAreMembersOfTheFederalHomeLoanBank	3	subsidiary
	cno	Interest Expense On Fhlb Borrowings InterestExpenseOnFhlbBorrowings	74200000	usd
	cno	Interest Expense On Fhlb Borrowings InterestExpenseOnFhlbBorrowings	17400000	usd
	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	85100000	usd
CY2023Q3	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount1 StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1	601800000	usd
	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	51000000	usd
	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.44
	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LITIGATION AND OTHER LEGAL PROCEEDINGS</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings </span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its subsidiaries are involved in various legal actions in the normal course of business, in which claims for compensatory and punitive damages are asserted, some for substantial amounts. We recognize an estimated loss from these loss contingencies when we believe it is probable that a loss has been incurred and the amount of the loss can be reasonably estimated. Some of the pending matters have been filed as purported class actions and some actions have been filed in certain jurisdictions that permit punitive damage awards that are disproportionate to the actual damages incurred. The amounts sought in certain of these actions are often large or indeterminate and the ultimate outcome of certain actions is difficult to predict. In the event of an adverse outcome in one or more of these matters, there is a possibility that the ultimate liability may be in excess of the liabilities we have established and could have a material adverse effect on our business, financial condition, results of operations and cash flows. In addition, the resolution of pending or future litigation may involve modifications to the terms of outstanding insurance policies or could impact the timing and amount of rate increases, which could adversely affect the future profitability of the related insurance policies. Based upon information presently available, and in light of legal, factual and other defenses available to the Company and its subsidiaries, the Company does not believe that it is probable that the ultimate liability from either pending or threatened legal actions, after consideration of existing loss provisions, will have a material adverse effect on the Company's consolidated financial condition, operating results or cash flows. However, given the inherent difficulty in predicting the outcome of legal proceedings, there exists the possibility that such legal actions could have a material adverse effect on the Company's consolidated financial condition, operating results or cash flows.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the inherent difficulty of predicting litigation outcomes, particularly those that will be decided by a jury, some matters purport to seek substantial or an unspecified amount of damages for unsubstantiated conduct spanning several years based on complex legal theories and damages models. The alleged damages typically are indeterminate or not factually supported in the complaint, and, in any event, the Company's experience indicates that monetary demands for damages often bear little relation to the ultimate loss. In some cases, plaintiffs are seeking to certify classes in the litigation and class certification either has been denied or is pending and we have filed oppositions to class certification or sought to decertify a prior class certification. In addition, for many of these cases: (i) there is uncertainty as to the outcome of pending appeals or motions; (ii) there are significant factual issues to be resolved; and/or (iii) there are novel legal issues presented. Accordingly, the Company cannot reasonably estimate the possible loss or range of loss in excess of amounts accrued, if any, or predict the timing of the eventual resolution of these matters. The Company reviews these matters on an ongoing basis. When assessing reasonably possible and probable outcomes, the Company bases its assessment on the expected ultimate outcome following all appeals.</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On April 9, 2019, Bankers Conseco Life Insurance Company ("BCLIC") and Washington National commenced an action entitled</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> Bankers Conseco Life Insurance Company and Washington National Insurance Company v. Wilmington Trust, National Association</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, in the Supreme Court of the State of New York, County of New York, Commercial Division (the "Wilmington Action"). BCLIC and Washington National seek an unspecified amount of damages, costs, attorney's fees, and other relief as the court deems appropriate. In the Wilmington Action, BCLIC and Washington National assert claims against Wilmington Trust, National Association ("Wilmington") for breaching its express contractual obligations under four trust agreements pursuant to which Wilmington was the trustee in regard to trust assets ceded as part of reinsurance agreements with Beechwood Re Ltd. ("BRe"), as well as for breaching its fiduciary duties to BCLIC and Washington National. The Court granted Wilmington's motion to dismiss this litigation. BCLIC and Washington National appealed the Court's decision. On April 20, 2021, the New York Appellate Division of the Supreme Court, First Judicial Department unanimously reversed the trial court and reinstated breach of contract and breach of fiduciary duty claims against Wilmington. The case has been resolved by settlement and dismissed.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 7, 2019, the Joint Official Liquidators of Platinum Partners Value Arbitrage Fund L.P. (in Official Liquidation) and Principal Growth Strategies, LLC, commenced suit against, among others, CNO Financial Group, Inc., BCLIC, Washington National and 40\|86 Advisors, Inc. (collectively, the "CNO Parties") in Delaware Chancery Court. Plaintiffs seek an unspecified amount of damages, costs, attorney's fees, and other relief as the court deems appropriate. Plaintiffs allege that the CNO Parties were unjustly enriched when they terminated BCLIC and Washington National's reinsurance agreements with BRe and recaptured assets from reinsurance trusts, in particular, Agera securities. Plaintiffs contend that the Agera securities were fraudulently transferred to the reinsurance trusts by other Platinum-related entities and they are seeking to claw back those Agera securities, or the value of those assets, from the CNO Parties. The CNO Parties are vigorously contesting the plaintiff's claims. The CNO Parties had removed the case to the United States District Court for the District of Delaware but on April 6, 2020, the District Court granted the plaintiff's motion to remand the case back to the Delaware Chancery Court. Plaintiffs have filed an Amended Complaint and the CNO Parties have moved to dismiss the Amended Complaint. The Delaware Chancery Court denied the CNO Parties’ motions to dismiss the Amended Complaint on the basis of forum non conveniens, but granted the CNO Parties’ motion to stay the case pending the conclusion of a related matter. After the stay is lifted, the court will address the CNO Parties’ and other defendants’ motions to dismiss the Amended Complaint on numerous other grounds.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On June 28, 2019, BCLIC and Washington National commenced an action entitled </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Bankers Conseco Life Insurance Company and Washington National Insurance Company v. KPMG LLP,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in the Supreme Court of the State of New York, County of New York, Commercial Division (the "KPMG Action"). BCLIC and Washington National seek an unspecified amount of damages, costs, attorney's fees, and other relief as the court deems appropriate. In the KPMG Action, BCLIC and Washington National assert claims against KPMG LLP ("KPMG") for aiding and abetting fraud, constructive fraud and negligent misrepresentation arising from KPMG's alleged role in the Platinum Partners' scheme to defraud BCLIC and Washington National into reinsuring its long-term care business with BRe. The Court granted KPMG’s motion to dismiss this litigation. BCLIC and Washington National appealed the Court's decision. On December 1, 2020, the New York Appellate Division of the Supreme Court, First Judicial Department unanimously reversed the trial court and reinstated the aiding and abetting claim against KPMG. The case has been resolved by settlement and dismissed.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 5, 2012, plaintiffs William Jeffrey Burnett and Joe H. Camp commenced an action entitled Burnett v. Conseco Life Ins. Co. against, among others, CNO Financial Group, Inc. and CNO Services, LLC (collectively, the "CNO Entities") in the United States District Court for the Central District of California on behalf of a putative class of former interest-sensitive whole life insurance policyholders who surrendered their policies or let them lapse. Plaintiffs' first amended complaint alleges that the CNO Entities are liable under an alter ego theory for Conseco Life Insurance Company's purported breach of the optional premium payment provision (the "Optional Premium Payment") of plaintiffs' insurance policies. In January 2018, the case was transferred to the United States District Court for the Southern District of Indiana. On August 17, 2020, the Court denied the CNO Entities' motions to dismiss. On January 13, 2021, the Court granted final approval of a class action settlement between plaintiffs and co-defendant Conseco Life Insurance Company (n/k/a Wilco Life Insurance Company). The case remains pending against the CNO Entities. On March 25, 2022, the Court certified a Rule 23(b)(3) class of under 2,000 policyholders who invoked the policy's Optional Premium Payment prior to October 2008 and who surrendered their policies between October 7, 2008 and September 1, 2011. The Court's certification order acknowledged the existence of individualized issues of causation and damages, which the Court stated could be addressed in individualized proceedings following a class trial on the alter ego allegations and the meaning of the subject insurance policy language. The CNO Entities continue to vigorously defend the case.</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Examinations and Fines</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Insurance companies face significant risks related to regulatory investigations and actions. Regulatory investigations generally result from matters related to sales or underwriting practices, payment of contingent or other sales commissions, claim payments and procedures, product design, product disclosure, additional premium charges for premiums paid on a periodic basis, denial or delay of benefits, charging excessive or impermissible fees on products, procedures related to canceling policies, changing the way cost of insurance charges are calculated for certain life insurance products or recommending unsuitable products to customers. We are, in the ordinary course of our business, subject to various examinations, inquiries and information requests from state, federal and other authorities. The ultimate outcome of these regulatory actions (including the costs of complying with information requests and policy reviews) cannot be predicted with certainty. In the event of an unfavorable outcome in one or more of these matters, the ultimate liability may be in excess of liabilities we have established and we could suffer significant reputational harm as a result of these matters, which could also have a material adverse effect on our business, financial condition, results of operations or cash flows.</span></div>
CY2019Q2	cno	Number Of Trust Agreements NumberOfTrustAgreements	4	trust_agreement
CY2022Q1	cno	Number Of Policyholders NumberOfPolicyholders	2000	policyholder
	us-gaap	Net Income Loss NetIncomeLoss	240200000	usd
	us-gaap	Net Income Loss NetIncomeLoss	592600000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	198500000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	184700000	usd
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	24600000	usd
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	154700000	usd
	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	169500000	usd
	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	-475000000.0	usd
	cno	Change In Accrued Investment Income Amortization Of Premium Or Discount On Investments And Fair Value Of Investments ChangeInAccruedInvestmentIncomeAmortizationOfPremiumOrDiscountOnInvestmentsAndFairValueOfInvestments	-54900000	usd
	cno	Change In Accrued Investment Income Amortization Of Premium Or Discount On Investments And Fair Value Of Investments ChangeInAccruedInvestmentIncomeAmortizationOfPremiumOrDiscountOnInvestmentsAndFairValueOfInvestments	132000000.0	usd
	us-gaap	Increase Decrease In Deferred Policy Acquisition Costs IncreaseDecreaseInDeferredPolicyAcquisitionCosts	277600000	usd
	us-gaap	Increase Decrease In Deferred Policy Acquisition Costs IncreaseDecreaseInDeferredPolicyAcquisitionCosts	248500000	usd
	cno	Gain Losson Investments Excluding Cash Expenses GainLossonInvestmentsExcludingCashExpenses	-79200000	usd
	cno	Gain Losson Investments Excluding Cash Expenses GainLossonInvestmentsExcludingCashExpenses	-99200000	usd
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	26700000	usd
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-105200000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	406200000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	334500000	usd
	cno	Share Based Compensation Noncash Portion ShareBasedCompensationNoncashPortion	18400000	usd
	cno	Share Based Compensation Noncash Portion ShareBasedCompensationNoncashPortion	19800000	usd
CY2023Q3	cno	Variable Interest Entity Amortized Cost Securities Held VariableInterestEntityAmortizedCostSecuritiesHeld	880600000	usd
CY2023Q3	cno	Variable Interest Entity Gross Unrealized Gains Fixed Maturity Securities VariableInterestEntityGrossUnrealizedGainsFixedMaturitySecurities	1900000	usd
CY2023Q3	cno	Variable Interest Entity Gross Unrealized Losses Fixed Maturity Securities VariableInterestEntityGrossUnrealizedLossesFixedMaturitySecurities	21500000	usd
CY2023Q3	cno	Variable Interest Entity Fixed Maturity Securities Allowance For Credit Loss VariableInterestEntityFixedMaturitySecuritiesAllowanceForCreditLoss	2900000	usd
CY2023Q3	cno	Variable Interest Entity Fixed Maturity Securities Fair Value VariableInterestEntityFixedMaturitySecuritiesFairValue	858100000	usd
	cno	Variable Interest Entities Net Realized Gain Loss On Investments VariableInterestEntitiesNetRealizedGainLossOnInvestments	4200000	usd
	cno	Variable Interest Entities Net Gain Loss From Sale Of Fixed Maturity Investments VariableInterestEntitiesNetGainLossFromSaleOfFixedMaturityInvestments	6800000	usd
	cno	Variable Interest Entities Change In Allowance For Current Expected Credit Losses VariableInterestEntitiesChangeInAllowanceForCurrentExpectedCreditLosses	-2600000	usd
	cno	Variable Interest Entity Investments Gross Investment Losses From Sale Before Tax VariableInterestEntityInvestmentsGrossInvestmentLossesFromSaleBeforeTax	6900000	usd
	cno	Variable Interest Entities Investments Sold VariableInterestEntitiesInvestmentsSold	18500000	usd
	cno	Variable Interest Entities Net Realized Gain Loss On Investments VariableInterestEntitiesNetRealizedGainLossOnInvestments	6700000	usd
	cno	Variable Interest Entities Net Gain Loss From Sale Of Fixed Maturity Investments VariableInterestEntitiesNetGainLossFromSaleOfFixedMaturityInvestments	3900000	usd
	cno	Variable Interest Entities Change In Allowance For Current Expected Credit Losses VariableInterestEntitiesChangeInAllowanceForCurrentExpectedCreditLosses	2800000	usd
	cno	Variable Interest Entity Investments Gross Investment Losses From Sale Before Tax VariableInterestEntityInvestmentsGrossInvestmentLossesFromSaleBeforeTax	3900000	usd
	cno	Variable Interest Entities Investments Sold VariableInterestEntitiesInvestmentsSold	55900000	usd
CY2023Q3	cno	Number Of Investments Held By Variable Interest Entities In Default NumberOfInvestmentsHeldByVariableInterestEntitiesInDefault	0	investment
CY2023Q3	cno	Investments Held In Limited Partnerships InvestmentsHeldInLimitedPartnerships	540100000	usd
CY2023Q3	cno	Unfunded Commitmentsto Limited Partnerships UnfundedCommitmentstoLimitedPartnerships	523700000	usd
	cno	Fair Value Fixed Maturity Securities Valued Using Broker Quotes Percentage FairValueFixedMaturitySecuritiesValuedUsingBrokerQuotesPercentage	0.79
CY2023Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001224608-23-000061-index-headers.html	Edgar Link	pending
0001224608-23-000061-index.html	Edgar Link	pending
0001224608-23-000061.txt	Edgar Link	pending
0001224608-23-000061-xbrl.zip	Edgar Link	pending
cno-20230930.htm	Edgar Link	pending
cno-20230930.xsd	Edgar Link	pending
cno-20230930_htm.xml	Edgar Link	completed
cno09302023ex311.htm	Edgar Link	pending
cno09302023ex312.htm	Edgar Link	pending
cno09302023ex321.htm	Edgar Link	pending
cno09302023ex322.htm	Edgar Link	pending
exhibit101-112023severance.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
cno-20230930_cal.xml	Edgar Link	unprocessable
cno-20230930_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
cno-20230930_pre.xml	Edgar Link	unprocessable
cno-20230930_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CNO
CNO Financial Group, Inc. Stock $cno

2023 Q4 Form 10-Q Financial Statement

#000122460823000061 Filed on November 08, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CNO CNO Financial Group, Inc. Stock $cno

2023 Q4 Form 10-Q Financial Statement

#000122460823000061 Filed on November 08, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CNO
CNO Financial Group, Inc. Stock $cno